Definitive Contract 75N93023C00024
Award Date
6/1/23
Potential Completion Date
5/2/25
Potential Value
$4.6M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Sorrento Therapeutics, Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
San Diego, CA 92121, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
19
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $4,469,522.01 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Agile Sciences, Inc., a small disadvantaged business. The contract is for "Targeting Therapeutics Development to Relieve Bottlenecks: Optimizing Lead Therapeutic Compounds Against Infectious Pathogens" and has an ultimate completion date of October 15, 2018. The contract was awarded on June 30, 2015 and was not set aside.
This $596,519 fixed-price federal contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Ampersand Biosciences LLC, a woman-owned small business. The contract is for the development of reagents to support immunologic analysis of non-mammalian and underrepresented mammalian models, such as ferrets and mice, under SBIR Topic 107. This aligns with NIAID's mission to conduct and support research to...
This $18,274,778 definitive contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to AN2 Therapeutics, Inc. The contract supports the development of epetraborole as a novel therapeutic for melioidosis and additional antimicrobial resistant bacterial biothreat pathogens. This award was issued under a Broad Agency Announcement (BAA) that also sought proposals for advanced vaccine and diagnostic development against biodefense and emerging...
This $1,797,717.00 Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the National Institutes of Health (NIH), to Intralytix Inc., a biotechnology company specializing in bacteriophage-based products. The contract is for the development of a "Universal, Scalable Artificial Intelligence-Based Platform for Manufacturing High Titer Biopharmaceuticals", which aligns with...
This is a new contract award by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services (HHS), to Trius Therapeutics, Inc., a for-profit organization. The contract, awarded under Broad Agency Announcement NIH-NIAID-DMID-08-20, is a definitive, cost-plus-fixed-fee contract with a ceiling value of $25,641,873.40 and an ultimate completion date of August 31, 2013. The contract does not have a set-aside designation. As NIAID is...
This is a $3,880,651.60 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Southwest Research Institute (SwRI) to optimize lead therapeutic compounds against infectious pathogens. The contract is not set aside. SwRI, a nonprofit research organization, will conduct research and development activities to help relieve bottlenecks in the development of targeted therapeutics. The contract includes three...
This is a $3,435,398.00 cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to Sri International, a non-profit research and development institute. The contract is for the development and testing of animal models for infectious diseases. This contract does not have a small business set-aside designation. Sri International frequently serves as a prime...
This is a cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the U.S. Department of Health and Human Services, to Sri International, a non-profit research and development institute. The contract, valued at $452,091.00, is for nonclinical services related to the development of interventional agents for infectious diseases. This award is part of a larger master indefinite delivery/indefinite quantity (IDIQ) contract...
This firm fixed-price delivery order contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Southern Research Institute, a non-profit research organization. The contract, valued at $26,480.00, is for "IN VITRO ASSESSMENTS FOR ANTIMICROBIAL ACTIVITY" and was awarded under the "In Vitro Antimicrobial Assessments 2011-2018" indefinite delivery/indefinite...
This is a $1,084,824.00 firm-fixed-price definitive contract awarded to Ampersand Biosciences LLC, a woman-owned small business, by the National Institute of Allergy and Infectious Diseases (NIAID) on September 30, 2024. The contract is for the further characterization and validation of monoclonal antibodies to study respiratory diseases. The work will be performed in Upper St Reg, NY 12945, USA and has an ultimate completion date of September 29, 2026. This contract does not have a set-aside...